To amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes.
Bill journey · stage 1 of 5
Just introduced
What it doesSummary introduced in house (Mar 3, 2020)
This bill expands existing requirements relating to supply shortages of life-saving drugs to also apply to life-saving medical devices.
Generally, a manufacturer must (1) notify the Food and Drug Administration (FDA) of supply interruptions in certain circumstances, (2) provide for the expedited review of a new device that may mitigate the shortage, and (3) allow the FDA to authorize the importation of the device for emergency medical care.
What just happenedMar 4, 2020
Sponsor introductory remarks on measure. (CR H1476)
Who’s behind it
- Introduced in HouseMar 3, 2020
- Mar 4, 2020IntroReferralB00100
Sponsor introductory remarks on measure. (CR H1476)
- Mar 3, 2020IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 3, 2020IntroReferralIntro-H
Introduced in House
- Mar 3, 2020IntroReferral1000
Introduced in House